A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

SuspendedOBSERVATIONAL
Enrollment

272

Participants

Timeline

Start Date

February 10, 2019

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Chronic Lymphocytic Leukemia (CLL)
Trial Locations (13)

13100

Ziv Medical Center /ID# 215462, Safed

91031

Shaare Zedek Medical Center /ID# 207896, Jerusalem

91120

Hadassah /ID# 207898, Jerusalem

1834111

HaEmek Medical Center /ID# 210900, Afula

2210001

Galilee Medical Center /ID# 207899, Nahariya

3109601

Rambam Health Care Campus /ID# 210320, Haifa

3339419

Bnai Zion Medical Center /ID# 206963, Haifa

4428164

Meir Medical Center /ID# 215466, Kfar Saba

4941492

Rabin Medical Center /ID# 206961, Petah Tikva

5265601

The Chaim Sheba Medical Center /ID# 207900, Ramat Gan

6423906

Tel Aviv Sourasky Medical Center /ID# 206962, Tel Aviv

7661041

Kaplan Medical Center /ID# 207902, Rehovot

8443901

Soroka University Medical Center /ID# 207897, Beersheba

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY